Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Account Payables: 2012-2025

Historic Change in Account Payables for Ani Pharmaceuticals (ANIP) over the last 13 years, with Sep 2025 value amounting to $13.8 million.

  • Ani Pharmaceuticals' Change in Account Payables rose 547.09% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 54.46%. This contributed to the annual value of $479,000 for FY2024, which is 93.66% down from last year.
  • Ani Pharmaceuticals' Change in Account Payables amounted to $13.8 million in Q3 2025, which was up 347.53% from $3.1 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Change in Account Payables high stood at $13.8 million for Q3 2025, and its period low was -$9.1 million during Q3 2022.
  • In the last 3 years, Ani Pharmaceuticals' Change in Account Payables had a median value of $3.1 million in 2025 and averaged $2.8 million.
  • Over the last 5 years, Ani Pharmaceuticals' Change in Account Payables had its largest YoY gain of 753.23% in 2022, and its largest YoY loss of 602.32% in 2022.
  • Ani Pharmaceuticals' Change in Account Payables (Quarterly) stood at $9.8 million in 2021, then climbed by 3.02% to $10.1 million in 2022, then plummeted by 72.38% to $2.8 million in 2023, then crashed by 345.36% to -$6.8 million in 2024, then skyrocketed by 547.09% to $13.8 million in 2025.
  • Its Change in Account Payables stands at $13.8 million for Q3 2025, versus $3.1 million for Q2 2025 and $5.5 million for Q1 2025.